Loading…
Black Diamond Therapeutics, Inc. is projected to rise to $2.05 by 2027, a +7% move from its current price of $1.91. BDTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.82 | $1.91 | $2.00 | +0.03% |
| Jul 13 | $1.79 | $1.91 | $2.04 | +0.07% |
| Jul 14 | $1.77 | $1.91 | $2.07 | +0.10% |
| Jul 15 | $1.74 | $1.91 | $2.10 | +0.13% |
| Jul 16 | $1.73 | $1.91 | $2.12 | +0.16% |
| Jul 17 | $1.71 | $1.91 | $2.14 | +0.20% |
| Jul 18 | $1.70 | $1.91 | $2.16 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.70 | $1.91 | $2.16 | +0.23% |
| Week 2 | $1.62 | $1.92 | $2.28 | +0.46% |
| Week 3 | $1.56 | $1.92 | $2.37 | +0.69% |
| Week 4 | $1.51 | $1.93 | $2.46 | +0.92% |
| Week 5 | $1.47 | $1.93 | $2.53 | +1.15% |
| Week 6 | $1.44 | $1.94 | $2.61 | +1.38% |
| Week 7 | $1.41 | $1.94 | $2.68 | +1.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Its lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc.
and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
BDTX trades with a current price of $2.01 and a market capitalization of $115.18M. It holds a rank of 4048. The 30-day range is $1.47 to $2.76 and the stock shows an annualized volatility of 90.
The near-term forecast begins neutral in 2026, with 2026 min $1.61, avg $2.01, max $3.02 and ROI 0; sentiment NEUTRAL, followed by 2027 min $1.61, avg $2.18, max $3.18 and ROI 8.4, 2028 min $1.59, avg $2.27, max $3.51 and ROI 13.2, and 2029 min $1.55, avg $2.32, max $3.74 and ROI 15.3, all with NEUTRAL sentiment.
A major floor 33.2% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
The nearest ceiling, 18.3% above — a clean break opens room to run.
A major ceiling 88.5% above — clearing it would confirm fresh momentum.
Key BDTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.95 | Sell | $1.92 | Sell |
| MA 10 | $1.89 | Buy | $1.89 | Buy |
| MA 20 | $1.80 | Buy | $1.91 | Sell |
| MA 50 | $2.25 | Sell | $2.12 | Sell |
| MA 100 | $2.35 | Sell | $2.32 | Sell |
| MA 200 | $2.79 | Sell | $2.53 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.68 | Neutral |
| Stoch RSI (14) | 73.28 | Neutral |
| CCI (20) | 65.49 | Neutral |
| Williams %R (14) | -36.17 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 18.63 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 63.83 | Neutral |
| TRIX (15) | -0.91 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 54.95 | Neutral |
| Momentum (10) | 0.21 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.94 | Sell |
| ADX (14) | 17.75 | Neutral |
| ATR (14) | 0.09 | Info |
Near-term technicals are NEUTRAL. RSI14 is 50, with the 50-day simple moving average at $2.36 and the 200-day simple moving average at $2.82. Key levels include support at $1.61 and resistance at $3.60. The 30-day range spans from $1.47 to $2.76, indicating limited upside pressure in the very near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.61 | $1.91 | $2.86 | 0% | Neutral | |
| $1.53 | $2.05 | $2.96 | +7% | Neutral | |
| $1.52 | $2.15 | $3.28 | +12% | Neutral | |
| $1.49 | $2.20 | $3.51 | +15% | Neutral | |
| $1.56 | $2.39 | $3.95 | +25% | Bullish | |
| $2.28 | $3.62 | $6.18 | +89% | Bullish | |
| $2.27 | $3.73 | $6.55 | +95% | Bullish | |
| $2.03 | $3.44 | $6.19 | +80% | Bullish | |
| $2.28 | $3.99 | $7.34 | +109% | Bullish | |
| $2.05 | $3.70 | $6.96 | +94% | Bullish | |
| $2.82 | $5.87 | $12.04 | +208% | Bullish | |
| $6.34 | $14.09 | $32.41 | +638% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.61 | $1.91 | $2.40 | +0.00% |
| August 2026 | $1.68 | $2.02 | $2.52 | +5.87% |
| September 2026 | $1.62 | $1.97 | $2.50 | -2.70% |
| October 2026 | $1.63 | $2.01 | $2.59 | +2.12% |
| November 2026 | $1.73 | $2.14 | $2.80 | +6.69% |
| December 2026 | $1.73 | $2.16 | $2.86 | +0.95% |
Click any year to see its month-by-month BDTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BDTX to range from $1.61 to $2.86 through 2026. The $1.91 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BDTX price prediction for 2027 points to an average of $2.05 (low $1.53, high $2.96) — a potential gain of +7% on today's $1.91. Price action looks broadly range-bound.
In 2028, BDTX is projected to trade between $1.52 and $3.28, averaging $2.15 — a potential gain of +12% from today's $1.91. That is up +5% on the projected 2027 average. A consolidation phase looks the most probable path here.
Black Diamond Therapeutics, Inc.'s 2029 outlook centres on $2.20, within a $1.49 to $3.51 range. That is up +2% on the projected 2028 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2030, BDTX could reach as high as $3.95, with a base case around $2.39 and support toward $1.56 — roughly +25% from $1.91. Buyers look set to stay in control over this stretch.
Expect BDTX to range from $2.28 to $6.18 through 2031. The $3.62 average target implies a +89% move from current prices. That is up +51% on the projected 2030 average. Momentum favours further upside here.
The BDTX price prediction for 2032 points to an average of $3.73 (low $2.27, high $6.55) — a potential gain of +95% on today's $1.91. Buyers look set to stay in control over this stretch.
In 2033, BDTX is projected to trade between $2.03 and $6.19, averaging $3.44 — a potential gain of +80% from today's $1.91. That is -8% versus the projected 2032 average. Momentum favours further upside here.
Black Diamond Therapeutics, Inc.'s 2034 outlook centres on $3.99, within a $2.28 to $7.34 range. That is up +16% on the projected 2033 average. That marks a +109% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BDTX could reach as high as $6.96, with a base case around $3.70 and support toward $2.05 — roughly +94% from $1.91. Momentum favours further upside here.
Expect BDTX to range from $2.82 to $12.04 through 2040. The $5.87 average target implies a +208% move from current prices. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BDTX price prediction for 2050 points to an average of $14.09 (low $6.34, high $32.41) — a potential gain of +638% on today's $1.91. Momentum favours further upside here.
Investing $1,000 in BDTX today (≈ 523.560209 BDTX) could be worth
$7,377.52
+$6,377.52 (+638%) by 2050 · US Dollar
Based on the average projected BDTX price of $14.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDTXwould be worth at today's price.
$1,000 invested in BDTX on Jul 10, 2025 (≈ 364.963502 BDTX) would be worth
$697.08
-$302.92 (-30.3%) today · 0.70× · US Dollar
Based on a BDTX entry price of $2.74 vs. today's $1.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.01 | $950.25 | -5.0% |
| 1 month ago | $1.85 | $1,032.43 | +3.2% |
| 3 months ago | $2.56 | $746.09 | -25.4% |
| 6 months ago | $2.64 | $723.48 | -27.7% |
| 1 year ago | $2.74 | $697.08 | -30.3% |
| All time (5.0y) ago | $11.15 | $171.3 | -82.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDTX forecast.
Our base-case forecast reaches $3.80 around 2034.
Implied market cap at $3.80: $217.75M
The multi-year forecast moves into a bullish trajectory from 2030 onward. In 2030 the min, avg, and max are $1.69, $2.63, and $4.42 respectively, with a 31 ROI and bullish sentiment. The years 2031–2035 show continued upside, with 2031 avg $3.99 and 2032 avg $4.02 (ROI 98.3 and 99.9 respectively), 2033 avg $3.77, 2034 avg $4.41, and 2035 avg $3.98 (ROI 87.3, 119.2, and 97.9).
By 2040 the forecast reaches avg $6.53 and max $13.63 (ROI 224.8, bullish), and by 2050 the min, avg, and max are $7.09, $15.76, and $36.24 respectively (ROI 684, bullish). This suggests substantial long-term upside with increasing volatility and risk, but these are estimates and not guarantees.
Tap a question to reveal the answer.
2030 min $1.69, avg $2.63, max $4.42; ROI 31; sentiment BULLISH.
Forecasts show neutral in 2026 with avg $2.01 and max $3.02 (ROI 0); then bullish long-term, with 2030 avg $2.63 and ROI 31, and 2050 max $36.24 with ROI 684. These are estimates and not guarantees.
Yes, 2050 max is $36.24; 2050 avg is $15.76; ROI 684; sentiment BULLISH.
Current price is $2.01 and market cap is $115.18M.
30-day range is $1.47 to $2.76.
Black Diamond Therapeutics, Inc. Community Discussion
0Share your Black Diamond Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.